CRIS Current Research Information System

COCCO, LUCIO ILDEBRANDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.711
AS - Asia 13.443
EU - Europa 12.289
AF - Africa 1.127
SA - Sud America 836
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 20
Totale 44.462
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.542
SG - Singapore 4.032
CN - Cina 3.356
VN - Vietnam 3.201
GB - Regno Unito 2.815
IT - Italia 2.431
DE - Germania 1.791
SE - Svezia 1.512
HK - Hong Kong 914
FR - Francia 761
IN - India 658
RU - Federazione Russa 629
BR - Brasile 575
UA - Ucraina 520
IE - Irlanda 402
JP - Giappone 303
ZA - Sudafrica 285
TG - Togo 279
NL - Olanda 262
KR - Corea 217
FI - Finlandia 214
EE - Estonia 212
SC - Seychelles 194
CI - Costa d'Avorio 169
AR - Argentina 119
CH - Svizzera 116
BG - Bulgaria 106
AT - Austria 105
CA - Canada 103
HR - Croazia 103
NG - Nigeria 102
JO - Giordania 87
BE - Belgio 85
BD - Bangladesh 80
ID - Indonesia 79
PH - Filippine 71
TH - Thailandia 64
TR - Turchia 57
PK - Pakistan 54
PL - Polonia 45
EC - Ecuador 40
GR - Grecia 39
MX - Messico 39
IQ - Iraq 38
ES - Italia 34
TW - Taiwan 31
SA - Arabia Saudita 29
UZ - Uzbekistan 29
MY - Malesia 26
AU - Australia 25
CO - Colombia 25
RO - Romania 23
IR - Iran 20
EG - Egitto 19
CL - Cile 18
PY - Paraguay 17
EU - Europa 15
VE - Venezuela 15
IL - Israele 14
LB - Libano 14
TN - Tunisia 14
ET - Etiopia 12
LT - Lituania 12
MA - Marocco 12
AE - Emirati Arabi Uniti 11
NP - Nepal 11
PE - Perù 11
PT - Portogallo 11
UY - Uruguay 11
HU - Ungheria 10
DZ - Algeria 9
KE - Kenya 9
NZ - Nuova Zelanda 9
DK - Danimarca 8
MD - Moldavia 7
OM - Oman 7
CZ - Repubblica Ceca 6
AL - Albania 5
AZ - Azerbaigian 5
DO - Repubblica Dominicana 5
JM - Giamaica 5
LV - Lettonia 5
QA - Qatar 5
SN - Senegal 5
BO - Bolivia 4
KZ - Kazakistan 4
LU - Lussemburgo 4
SI - Slovenia 4
SY - Repubblica araba siriana 4
AO - Angola 3
BW - Botswana 3
CR - Costa Rica 3
KG - Kirghizistan 3
MN - Mongolia 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BF - Burkina Faso 2
Totale 44.415
Salva come PNG Salva come JPEG
Città #
Singapore 2.757
Southend 2.447
Ashburn 1.725
Fairfield 1.674
Chandler 1.237
Santa Clara 968
Hong Kong 866
Houston 806
Woodbridge 786
Bologna 752
Wilmington 717
Ann Arbor 700
San Jose 690
Seattle 667
Ho Chi Minh City 646
Cambridge 586
Princeton 586
Hanoi 517
Beijing 489
Dong Ket 487
Boardman 411
Dublin 401
Hefei 304
Jacksonville 292
Lomé 279
Lauterbourg 275
Nanjing 267
Westminster 259
Padova 251
Tokyo 224
Dallas 206
Frankfurt am Main 193
Berlin 182
Los Angeles 180
Helsinki 171
Abidjan 169
Milan 157
New York 156
Buffalo 152
Jinan 135
Saint Petersburg 135
San Diego 124
Shenyang 116
Sofia 105
Da Nang 104
Changsha 102
Seoul 100
Abeokuta 98
Nanchang 90
Council Bluffs 89
Redondo Beach 89
Bern 88
Florence 85
Amman 84
Guangzhou 83
Haiphong 82
Brussels 79
Munich 78
Redwood City 77
Hebei 73
Turin 73
Medford 70
Vienna 69
Shanghai 68
São Paulo 65
Mülheim 62
Chicago 60
Johannesburg 57
Rome 56
Bremen 53
London 53
Zhengzhou 48
Des Moines 47
Orem 47
Falls Church 46
Tianjin 46
Norwalk 45
Redmond 44
Dearborn 42
Nuremberg 42
Amsterdam 40
Hangzhou 40
Jakarta 40
Haikou 39
Jiaxing 38
Toronto 36
Yubileyny 35
Kunming 33
Phoenix 33
Verona 33
Falkenstein 32
Mahé 32
Atlanta 31
Bangkok 31
Moscow 31
Ningbo 31
Warsaw 31
Hải Dương 30
Montreal 30
Mountain View 30
Totale 28.417
Salva come PNG Salva come JPEG
Nome #
Multiple roles of phosphoinositide-specific phospholipase C isozymes. 396
Cell signaling pathways in autosomal-dominant leukodystrophy (ADLD): the intriguing role of the astrocytes 341
Ankrd2/ARPP is a novel Akt2 specific substrate and regulates myogenic differentiation upon cellular exposure to H(2)O(2 288
Clinical and molecular insights in erythropoiesis regulation of signal transduction pathways in myelodysplastic syndromes and β-thalassemia 281
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 279
Near-peer teaching in human anatomy from a tutors’ perspective: An eighteen-year-old experience at the university of Bologna 274
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 272
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes 256
ALIVE CEROPLASTICS 4D Representations 254
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 252
Impact of phospholipase C β1 in glioblastoma: a study on the main mechanisms of tumor aggressiveness 249
Inositide-Dependent Nuclear Signalling in Health and Disease 245
Endoscopic endonasal anatomy of the ophthalmic artery in the optic canal 244
Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs 238
A role for PKCepsilon during C2C12 myogenic differentiation 237
Cancer therapy and treatments during COVID-19 era 229
Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. 227
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 226
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes 224
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 222
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 221
BMP-2 Induced Expression of PLCβ1 That is a Positive Regulator of Osteoblast Differentiation 221
Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. 219
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 219
Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes 219
Catalytic activity of nuclear PLC-beta(1) is required for its signalling function during C2C12 differentiation. 217
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 217
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 215
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 213
AKT-dependent phosphorylation of the adenosine deaminases ADAR-1 and -2 inhibits deaminase activity 210
Communication between median and musculocutaneous nerve at the level of cubital fossa - A case report 208
PLC-β1 and cell differentiation: An insight into myogenesis and osteogenesis 207
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 207
Nuclear inositide signaling and cell cycle 206
Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells 206
Role of PLCγ1 in the modulation of cell migration and cell invasion in glioblastoma 206
Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases 204
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 203
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes 203
Nuclear phospholipase C isoenzyme imbalance leads to pathologies in brain, hematologic, neuromuscular, and fertility disorders 203
Nuclear Inositide Signaling via Phospholipase C 201
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 200
Endoscopic endonasal approach to primitive Meckel's cave tumors: a clinical series 200
Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia 200
Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS 197
Aberrant expression of B203.13 antigen in acute lymphoid leukemia of B-cell origin. 197
Lamin B1 accumulation’s effects on autosomal dominant leukodystrophy (ADLD): Induction of reactivity in the astrocytes 197
Nuclear Localization of Diacylglycerol Kinase Alpha in K562 Cells Is Involved in Cell Cycle Progression 196
Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology 195
Revisiting nuclear phospholipase C signalling in MDS 194
The wide and growing range of lamin B‑related diseases: from laminopathies to cancer 194
Intranuclear 3'-phosphoinositide metabolism and Akt signaling: New mechanisms for tumorigenesis and protection against apoptosis? 192
Nuclear inositide specific phospholipase C signalling - interactions and activity 192
Nuclear inositides: facts and perspectives. 189
Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines. 187
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 186
IPMK and β-catenin mediate PLC-β1-dependent signaling in myogenic differentiation 186
Anatomical variations of the right renal and spermatic arteries: a case report 185
Inositide signaling: Nuclear targets and involvement in myelodysplastic syndromes 184
Nuclear diacylglycerol kinase-theta is activated in response to nerve growth factor stimulations of PC12 cells 183
Inositide signaling in the nucleus: From physiology to pathology. 183
Phosphoinositide-dependent signaling in cancer: A focus on phospholipase C isozymes 183
Regulation of nuclear phospholipase C activity 182
Frequent Elevation of Akt Kinase Phosphorylation in Blood Marrow and Peripheral Blood Mononuclear Cells from High Risk myelodysplastic Syndrome Patients 182
Multiple forms of PKR present in the nuclei of acute leukemia cells represent an active kinase that is responsive to stress 182
Therapeutic potential of nvp-bkm120 in human osteosarcomas cells 181
Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS) 181
Subcellular localization relevance and cancer-associated mechanisms of diacylglycerol kinases 181
eEF1A phosphorylation in the nucleus of insulin-stimulated C2C12 myoblasts: Ser53 is a novel substrate for protein kinase C βI 178
Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. 178
Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins. 178
A role for PLCbeta1 in myotonic dystrophies type 1 and 2. 177
Expression of signal transductions proteins during the differentiation of primary human erythroblasts 176
Inositide-specific phospholipase c beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia 176
Application of flow cytometry to molecular medicine: Detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts 176
Unilateral absence of Casserio’s nerve and a communicating branch to the median nerve. An additional variant of brachial flexors motor innervation 176
Phospholipase C-β1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation 176
Advances in MDS/AML and inositide signalling 174
Advances in Targeting Signal Transduction Pathways. 173
A role for PKR in hematologic malignancies 173
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 173
Nuclear phospholipase C beta1 and cellular differentiation. 172
Physiology and pathology of nuclear phospholipase C beta1 172
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 172
Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression 171
Advances in Enzyme Regulation 171
Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics 171
Nuclear inositol lipid metabolism: more than just second messenger generation? 170
Expression of phospholipase C beta family isoenzymes in C2C12 myoblasts during terminal differentiation. 170
Signal transduction within the nucleus: Revisiting phosphoinositide inositide-specific phospholipase Cbeta(1). 169
Protein kinase C involvement in cell cycle modulation 169
Signaling pathways and bone marrow microenvironment in myelodysplastic neoplasms 168
Expression of phosphoinositide-specific phospholipase C isoenzymes in cultured astrocytes 168
Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C 168
Diacylglycerol kinase (DGK) involvement in K562 erythroleukemia cell proliferation 167
A role of PI-PLCb1 in G1/S transition in human erythroleukemia k562 cells 166
Signaling Role of Pericytes in Vascular Health and Tissue Homeostasis 165
Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter 165
Hepato-gastric and spleno-mesenteric arterial trunks: anatomical variation report and review of literature 165
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 165
Totale 20.256
Salva come PNG Salva come JPEG
Categoria #
all - tutte 123.842
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 123.842
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.466 0 0 0 0 0 0 0 0 0 186 159 1.121
2021/20225.558 549 132 354 471 461 313 159 360 178 773 923 885
2022/20235.724 597 742 327 780 459 427 288 339 897 121 411 336
2023/20241.916 109 302 180 188 221 330 95 69 91 134 76 121
2024/20256.229 215 949 615 353 1.309 337 453 232 105 303 200 1.158
2025/202612.646 959 1.337 1.394 927 1.735 940 1.634 498 2.473 749 0 0
Totale 45.350